Pharmacodynamic modelling of levodopa, 3-O-methyldopa and their effects: An application of the Dixon equation

Pharmacological Research

Volumn 39, Issue 3, 1999, Pages 203-210

  Wu, Guang ^a   Furlanut, Mario ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

Dixon equation; Levodopa; Parkinson's disease; Pharmacodynamic modelling

Indexed keywords

3 O METHYLDOPA; ANTIPARKINSON AGENT; CARBIDOPA PLUS LEVODOPA; LEVODOPA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; MALE; MODEL; PARKINSON DISEASE; PHARMACODYNAMICS; PRIORITY JOURNAL;

EID: 0033106169     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.1998.0435     Document Type: Article

References (40)

1. Bredberg E, Tedroff J, Aquilonius SM, Paalzow L. Pharmacokinetics and effects of levodopa in advanced Parkinson's disease. Eur J Clin Pharmacol 1990; 39: 385-9.
2. Bowes SG, O'Neill CJA, Nicholson PW, Leeman AL, Deshmukh AA, Dobbs RJ, Dobbs SM. Effect of duration of levodopa/decarboxylase inhibitor therapy on the pharmacokinetic handing of levodopa in elderly patients with idiopathic Parkinson's disease. Eur J Clin Pharmacol 1991; 41: 459-62.
3. Wade LA, Katzman R. 3-O-methyldopa uptake and inhibition of L-DOPA at the blood-brain-barrier. Life Sci 1975; 17: 131-6.
4. Benetello P, Furlanut M, Fortunato M, Pea F, Baraldo M. Levodopa and 3-O-methyldopa in cerebrospinal liquid after levodopa-carbidopa association. Pharmacol Res 1997; 35: 313-15.
5. Nutt JG, Woodword WR, Gancher ST, Merrick D. 3-O-methyldopa and the response to levodopa in Parkinson's disease. Ann Neurol 1987; 21: 584-8.
6. Nelson MV, Berchou RC, LeWitt PA, Kareti D, Galloway MP. Pharmacodynamic modeling of concentration-effect relationships after controlled-release carbidopa/levodopa (Sinemet CR4) in Parkinson's disease. Neurology 1990; 40: 70-4.
7. Nutt JG, Woodward WR, Cater JH, Gancher ST. Effect of long-term therapy on the pharmacodynamic of levodopa: Relation to on-off phenomenon. Arch Neurol 1992; 49: 1123-30.
8. Harder S, Baas H, Bergemann N, Demisch L, Rietbrock S. Concentration-effect relationship of levodopa in patients with Parkinson's disease after oral administration of an immediate release and a controlled release formulation. Br J Clin Pharmacol 1995; 39: 39-44.
9. Contin M, Riva R, Martinelli P, Cortelli P, Albani F, Baruzzi A. Pharmacodynamic modeling of oral levodopa: Clinical application in Parkinson's disease. Neurology 1993; 43: 367-71.
10. Marion MH, Stocci F, Quinn NP, Jenne P, Marsden CD. Repeated levodopa infusions in fluctuating Parkinson's disease: Clinical and pharmacokinetic data. Clin Neuropharmacol 1986; 9: 165-81.
11. Ledrtora JJL, Atkinson AJ, Kushner W, Nevin MJ, Lee WK, Jones C, Schmid FR. Long term antiarrhythmic therapy with N-acetylprocainamide. Clin Pharm 1979; 25: 273-82.
12. Schroeder P, Klitgaard NA, Simensen E. Significance of the acetylation phenotype and the therapeutic effect of procainamide. Eur J Clin Pharmacol 1979; 15: 63-8.
13. Elson J, Strong JM, Lee WK, Atkinson AJ. Antirrythmic potency of N-acetylprocainamide. Clin Pharmacol Ther 1975; 17: 134-40.
14. Whiting B, Holford NHG, Sheiner LB. Quantitative analysis of the disopyramide concentration-response relationship. Br J Clin Pharmacol 1980; 9: 67-75.
15. Eichelbaum M, Birkel P, Grube E, Gutgemann U, Somogyi A. Effects of verapamil on P-R intervals in relation to verapamil plasma levels following single i.v. and oral administration and during chronic treatment. Klin Wochenschr 1980; 58: 919-25.
16. Nissinen E, Taskinen J. Simultaneous determination of carbidopa, levodopa and 3,4-dihydroxyphenylacetic acid using high-performance liquid chromatography with electrochemical detection. J Chromatogr 1982; 231: 459-62.
17. Mean MA, Muradas D, Bazan E, Reiriz J. de Yebenes JG. Pharmacokinetics of L-dopa in patients with Parkinson's disease. Adv Neurol 1987; 45: 481-6.
18. Sagnella GA. Estimation of kinetic constants in ion transport studies: Regression analysis and Monte-Carlo simulation Clin Sci 1994; 87: 371-81.
19. PCNONLIN: Software for the Statistical Analysis on Nonlinear Models on Micros. Version 4.0 North Carolina: Scientific Consulting, Inc., 1992.
20. Garbrielsson J, Weiner D. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications. Stockholm: Swedish Pharmaceutical Press, 1994: 68-9.
21. Wu G, Furlanut M, Baraldo M, Pea F, Damiani D, Baccarani M. Prediction of cyclosporine blood concentrations in hematological patients with multidrug resistance. Pharmacol Res 1995; 31(suppl): 44.
22. Wu G, Baraldo M, Furlanut M. Calculating percentage prediction error: A user's note. Pharmacol Res 1995; 32: 241-8.
23. Wu G. Prediction of uptake of methyl mercury by rat erythrocytes using a two-compartment model. Arch Toxicol 1995; 70: 34-42.
24. Wu G, Baraldo M, Pea F, Cossettini P, Furlanut M. Effects of different sampling strategies on predictions of blood cyclosporine concentrations in haematological patients with multidrug resistance by bayesian and non-linear least squared methods. Pharmacol Res 1995; 32: 355-62.
25. Wu G, Cossettini P, Furlanut M. Prediction of blood cyclosporine concentrations in haematological patients with multidrug resistance by one-, two- and three-compartment models using bayesian and non-linear least squares methods. Pharmacol Res 1996; 34: 47-57.
26. Wu G, Furlanut M. Prediction of blood cyclosporine concentrations in haematological patients with multidrug resistance by means of total, lean and different adipose dosing body weight using bayesian and non-linear least squares methods. Int J Clin Pharmacol Res 1996; 16: 89-97.
27. Wu G, Furlanut M. Prediction of serum vancomycin concentrations by means of six different equations for calculation of creatinine clearance. Int J Clin Pharmacol Res 1997; 17: 1-10.
28. Wu G, Pea F, Cossettini P, Furlanut M. Effect of the number of samples on bayesian and non-linear least-squares individualization: A study of cyclosporine treatment of haematological patients with multidrug resistance. J Pharm Pharmacol 1998; 50: 343-9.
29. Wu G, Furlanut M. Prediction of serum vancomycin concentrations using one-, two- and three-compartment models with the implemented population pharmacokinetic parameters and the bayesian method. J Pharm Pharmacol 1998; 50: 851-6.
30. Healy MJR. Outliers in clinical chemistry quality-control schemes. Clin Chem 1979; 25: 675-7.
31. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981; 9: 503-12.
32. Wu G. Calculating predictive performance: A user's note. Pharmacol Res 1995; 31: 393-9.
33. Prichard MN, Shipman CJR. A three-dimensional model to analyze drug-drug interactions. Antiviral Res 1990; 24: 181-206.
34. Prichard MN, Prichard LE, Baguley WA, Nassiri MR, Shipman CJR. Three-dimensional analysis of the synergistic cytotoxicity of gancyclovir and zidovudine. Antimicrob Agents Chemother 1991; 35: 1060-5.
35. Johnson RA, Wichern DW. Applied Multivariate Statistical Analysis. 3rd Edn. New York: Prentice-Hall International, 1992: 20-8.
36. Lotta T, Vidgren J, Tilgmann C, Ulmanen I, Melén K, Julkunen I, Taskinen J. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: A revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 1995; 34: 4202-10.
37. Calne DB, Reid JL, Vakil SD. Parkinsonism treated with 3-O-methyldopa. Clin Pharmacol Ther 1973; 14: 386-9.
38. Sharpless NS, Muenter MD, Tyce GM. 3-methoxy-4-hydroxyphenylalanine (3-O-methyldopa) in plasma during oral L-dopa therapy of patients with Parkinson's disease. Clin Chim Acta 1972; 37: 359-69.
39. Kurama IL, Bartholini G, Tissot R, Plerscher A. The metabolism of L-3-O-methyldopa, a precursor of dopa in man. Clin Pharmacol Ther 1971; 12: 678-82.
40. Nutt JG, Fellman JH. Pharmacokinetics of levodopa. Clin Neuropharmacol 1984; 1: 35-49.